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The Role of Thrombolytic Therapy in Obstructive Thrombosed Mechanical Mitral Valve
Sagger Mawri, MD; Ferras Dabbagh, MD; Nancy Ly MD; Rajan Shah, MD; Sachin Parikh, MD; Marvin Eng, MD, William O’Neill, MD
Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI

Background
• Thrombosis is an uncommon complication of
mechanical prosthetic heart valves with an incidence
of 0.3-6% per patient-year.
• Early recognition of obstructive thrombosed prosthetic
heart valves (OTPHV) is crucial to prevent delays in
treatment and avoid significant morbidity and
mortality.
• No standard approach to treatment exists. The choice
between surgery, thrombolysis and escalation of
anticoagulation is considered on an individual basis.
• Here, we present a case of recurrent obstructive
thrombosed mechanical mitral valve and discuss
management strategies

Discussion

Fig 1. Fixed prosthetic mitral valve occluder on cinefluoroscopy

Case Presentation
• A 69 year-old male presents with worsening shortness of
breath for four months. The patient has a history of liver
transplant for alcoholic liver cirrhosis, subdural
hematoma, and St. Jude bileaflet mechanical mitral and
aortic valve replacements in 2007 for severe MR and
moderate to severe AI
• The patient’s dyspnea was initially attributed to angina,
for which he underwent coronary angiogram and
received 1 drug eluting stent to the LAD, with no
improvement in symptoms
• Because of his immunosuppressed state, he was thought
to have pneumonia and treated with no improvement
• The patient was transferred to us for failure of symptom
improvement. A TTE revealed prosthetic mitral valve
obstruction with a mean gradient of 18.8 mmHg and
pressure half time of 173 ms with normal heart rate
• TEE revealed a fixed occluder with atrial-side
echodensities consistent with thrombus, likely formed
after interruptions in Coumadin for outpatient procedures
• We performed thrombolysis based on the Ultraslow
PROMETEE trial. This involved intermittent infusions
of 25 mg of tissue plasminogen activator (tPA) over 25
hours with Doppler echocardiography between cycles to
document reductions in transvalvular gradients.
• After the first infusion, his transmitral gradient fell to 7
mmHg. The patient received 65 mg of tPA total.

Fig 2. Atrial side echodensities on prosthetic mitral valve

• He was discharged home with higher INR goal of 3.5-4.5
• Cinefluoroscopy (CF) performed one month later revealed
a persistently frozen occluder; however, with no symptoms
• One year later, he presented with recurrent similar
symptoms. TTE showed MV obstruction with mean
gradient of 28 mmHg, with frozen anterior leaflet on CF.
• Higher dose of tPA (50mg over 12 hrs) was delivered, with
complete resolution of his gradients and which freed his
mitral mechanical prosthesis on CF
• Six months later he developed recurrent mechanical MV
thrombosis and planned to undergo surgery; however, due
to incidental lung mass on CT concerning for malignancy
(possibly cause of prothrombotic state) this was deferred
• tPA per Ultraslow PROMETEE trial was again successful

• Prosthetic valve thrombosis is a rare but serious
complication of heart valve replacement.
• The 2014 ACC/AHA guidelines recommend thrombolytic
therapy (TT) in all right sided heart valves and certain left
sided heart valves with small thrombus area (<0.8 cm2). In
clinical practice, TT is applied more widely.
• Mortality rates between TT and surgery are comparable or
favor thrombolysis over surgery. In a large literature
search by Huang in JACC 2013, TT had 8-12% mortality,
whereas surgery had 15% at 30 days. Another study
published by Castilho in 2014 revealed a larger mortality
difference between surgery and TT with rates of 18.1 and
6.6%, respectively.
• This has led some clinicians to argue that TT should be
used as first line treatment in all patients with OTPHV
unless specific contraindications exist.
• There are many ways to deliver thrombolysis. No one way
is correct. The largest prospective non-randomized clinical
trial that attempts to compare the different thrombolysis
regimens is the TROIA study. It shows that low dose slow
infusion of tPA (25 mg over 6 hours) was superior to
higher doses and faster infusions of tPA or streptokinase
with regards to efficacy and safety.
• The Ultraslow-PROMETEE trial expanded on this study
by prolonging the infusion time of 25 mg tPA to 25 hours.
They found that the rate of intracranial hemorrhage fell
from 0.8% in the TROIA study to 0% without
compromising efficacy.
• The PROMETEE trial recommends successive infusions
of tPA up to a total dose of 200 mg as needed to achieve
complete thrombus resolution. Given our promising
early TTE findings and desire to avoid bleeding, the
patient was discharged after 65 mg of tPA. His INR goal
was raised to 3.5-4.5 as discussed in the 2014
ACC/AHA valve guidelines.
• In spite of a persistently frozen occluder by CF initially,
we surmise that the patient’s symptoms and
transvalvular gradients improved dramatically after a
few cycles of tPA due to dissolution of a large thrombus
burden.
• Subsequent cycles of tPA per the Ultraslow PROMETEE
protocol and higher dose both were successful

Fig 3. Elevated mean gradient through prosthetic mitral valve

Conclusions
• OTPHV is a life-threatening complication that requires
a high index of suspicion to make the correct diagnosis.
• The biggest risk factor for thrombosis is subtherapeutic
anticoagulation.
• TTE and TEE are useful diagnostic aids and can be
used to track response to therapies.
• While the choice between surgery and TT for the initial
management of OTPHV remains controversial, recent
studies show that TT is noninferior to surgery in terms
of efficacy and safety, even in patients with a history of
stroke.
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